Lymph Node Yield Thresholds for Oral Cancer Survival After Immunochemotherapy

Henan Cancer Hospital data from 2019-2022 defines surgical quality benchmarks for oral squamous cell carcinoma. The dataset includes a training cohort of 256 patients and an independent validation cohort of 199 patients from the First Affiliated Hospital of Zhengzhou University (2020-2022). It establishes thresholds for lymph node dissection adequacy associated with 3-year overall survival.

Use Cases

• Define surgical quality benchmarks based on lymph node yield thresholds mentioned in the description.
• Validate survival prediction models based on the established lymph node count thresholds.
• Analyze the association between surgical extent and complication rates based on the described patient stratification.
• Compare treatment outcomes between neoadjuvant immunochemotherapy cohorts based on the described patient groups.

Strengths

• Includes an external validation cohort of 199 patients, supporting generalizability.
• Defines specific, evidence-based thresholds (20 nodes for unilateral, 18 per side for bilateral dissection).
• Reports hazard ratios and confidence intervals for survival outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the two hospitals in Henan, China.

Provenance

Source

Shuai Yuan via figshare.

Collection Method

Clinical records from patients treated with neoadjuvant immunochemotherapy and surgery.

Time Range

Training cohort: 2019-2022. Validation cohort: 2020-2022.

Freshness

Last updated 2026-06-03 05:43:02; freshness should be verified.

Geography

Patients from Henan Cancer Hospital and the First Affiliated Hospital of Zhengzhou University in Henan, China.